Clinical trial · Interventional
Study of Tarceva and Targretin in Stage I-II Lung Cancer
A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer
NCT00125372CI-TRIAL-00036385completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-small-cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| erlotinib (Tarceva) and bexarotene (Targretin) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Erlotinib and Bexarotene
- description
- Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
- interventionNames
- Drug: erlotinib (Tarceva) and bexarotene (Targretin)
Primary outcomes (3)
- measure
- Number of Participants With Change in Expression Level of EGFR.
- timeFrame
- Baseline and 9 days
- measure
- Number of Participants With Change in Expression Level of Cyclin D1
- timeFrame
- Baseline and 9 days
- measure
- Number of Participants With Change in Expression Level of Phosphorylated EGFR (pEGFR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Resectable stage I or II non-small-cell lung cancer * Prior tissue biopsy (not cytology) available for research analysis * Adequate hepatic and renal function Exclusion Criteria: * Prior chemotherapy or radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.